CYTK — Q2 2026 Financial Report Analysis

Cytokinetics' second quarter was its first full quarter selling MYQORZO (aficamten), its heart drug for obstructive hypertrophic cardiomyopathy (oHCM, an inherited thickening of the heart muscle that blocks blood flow out of the heart). MYQORZO brought in $25.3 million of net product revenue, up from $4.8 million in the launch quarter (sales began in the last week of January). Total revenue still fell 57% from a year ago to $28.6 million, because Q2 2025 included a one-time $64.4 million payment from partner Bayer. Spending on the launch pushed the net loss to $198.8 million, or $1.50 per share. The balance sheet changed more than the income statement: a May share sale raised $760.1 million, and cash and investments ended the quarter at $1.70 billion.

At a glance

• $23.0 million of U.S. MYQORZO sales, nearly 5x Q1's $4.8 million. As of June 30, over 700 doctors had prescribed it, about 1,500 patients had received it, and over 80% of patients on therapy were on a paid prescription rather than free starter drug.
• $305.3 million of cash used in operations in the first half. That is roughly $150 million a quarter, against $1.70 billion of cash and investments and an undrawn $175 million loan tranche.
• Full-year spending guidance raised to $860–890 million (research plus selling and administrative costs, from $830–870 million). Management attributes the increase to preparing a 2027 launch in non-obstructive HCM after the ACACIA-HCM trial succeeded.

The quarter in numbers

For the first half, total revenue was $48.0 million (H1 2025: $68.3 million) and the net loss was $404.8 million (H1 2025: $295.7 million). Operating margin, the share of revenue left after running costs, isn't a useful measure here: operating costs were about seven times revenue.

The launch: what the sales figures show

Net product revenue is what MYQORZO sales bring in after discounts, rebates and other price deductions. The quarterly progression:

Q1 is calculated from the first-half total of $30.1 million minus Q2's $25.3 million. U.S. growth is real demand: the company says it comes from "expanding physician adoption and increasing patient access." The European $2.4 million is different. It comes from the June launch in Germany, and the earnings release describes it as "initial inventory purchased by distributors in Germany." A one-time filling of distributor shelves like this doesn't repeat at the same rate, so Q3 Europe sales may be lower than Q2 even if more patients are being treated.

MYQORZO is a cardiac myosin inhibitor: it reduces how hard the heart muscle squeezes. It competes with Bristol-Myers Squibb's Camzyos, which reached the market first. In its 10-Q, Cytokinetics says its market research supports eventually taking "greater than 50% market share" in the U.S. The ~1,500 patients and 700+ prescribers at the end of June are the first hard numbers to compare that ambition against. On August 13, the company asked a Delaware court to declare that MYQORZO does not infringe a BMS/MyoKardia patent (U.S. Patent No. 12,616,697) and that the patent is invalid. That case is worth watching because it bears on launch risk.

Where the money went

• Selling, general & administrative (SG&A) rose $38.7 million to $104.4 million. The 10-Q attributes this to "external costs associated with the commercial launch of MYQORZO and higher personnel related costs, including stock-based compensation." Stock-based compensation, meaning employee pay in shares rather than cash, was $19.8 million of SG&A, up from $14.0 million.
• R&D fell $12.3 million to $97.8 million. The drop reflects "higher clinical trial activity, supply chain costs and medical affairs activities in 2025." The big aficamten trials (MAPLE-HCM, ACACIA-HCM) are finished, and external aficamten costs fell from $27.5 million to $14.9 million. Omecamtiv mecarbil's external costs more than doubled to $8.8 million as its COMET-HF Phase 3 trial enrolls.
• Below the operating line, financing costs totaled $34.8 million: $14.7 million of interest on debt plus a $20.2 million non-cash interest charge on the aficamten royalty deal with Royalty Pharma. Interest income of $13.9 million and $1.3 million of net fair-value gains offset part of that, which is how a $179.2 million operating loss became a $198.8 million net loss.

What the headline numbers hide

• The revenue decline doesn't reflect the business shrinking. Q2 2025 included $64.4 million of Bayer license and milestone revenue: $52.4 million for delivering the Japan license and technology transfer, plus $11.8 million of clinical milestones. Strip that out and revenue from ongoing sources went from $2.4 million to $28.6 million.
• Cash burn is smaller than the net loss. First-half operating cash outflow was $305.3 million, compared with a $404.8 million net loss. The gap is mostly non-cash charges: $66.1 million of stock-based compensation, $39.0 million of non-cash royalty-liability interest and $17.2 million of non-cash debt interest. That accounting cuts both ways. The share pay costs nothing in cash, but it dilutes existing shareholders.
• The cost of goods sold flatters the margin, and Q2's cost was mostly a one-off. Cost of goods sold was $2.7 million on $25.3 million of sales. The 10-Q says this "reflects a charge related to drug supply optimization which accounts for nearly the entire amount." Drug made before the December 2025 approval was already charged to R&D, so cost of goods sold "for the next several quarters are expected to reflect a lower average per unit cost of materials." The gross margin will look unusually high until that pre-approval stock runs out.
• Receivables are large relative to sales. Product-related accounts receivable (sales not yet paid for) were $21.5 million at June 30, against $25.3 million of Q2 product revenue. That is normal early in a launch that sells through specialty pharmacies and distributors, and German distributor stocking was billed in June. Still, watch whether receivables keep growing faster than sales.
• The royalty liability is getting more expensive. Cytokinetics sold Royalty Pharma 4.5% of aficamten sales up to $5 billion a year. The interest rate implied on that liability rose to about 26.1% from 20.5% a year earlier. That implies the company now expects to pay more in future royalties, which is consistent with higher sales expectations, but it pushes up the non-cash interest charge each quarter.
• Per-share figures benefit from dilution. Weighted shares rose 10.6% to 132.1 million, so the loss per share widened 33.9% while the net loss widened 47.9%. The May offering (11.3 million shares at $71.00) and the conversion of the remaining $21.1 million of 2026 convertible notes into 2.0 million shares will raise the share count further in Q3.

Balance sheet and runway

Cash, cash equivalents and investments were $1.70 billion at June 30, up from $1.22 billion at year-end. Excluding the $760.1 million offering, the underlying balance fell by roughly $273 million over six months. Against that, the company carries:

• $890.5 million of convertible notes (principal) still outstanding: $140.5 million due 2027 (convertible by holders as of June 30, because the stock price passed the trigger) and $750.0 million due 2031.
• $275 million drawn on Royalty Pharma term loans. Each tranche repays 190% of principal in total over 10 years, and payments in 2026 come to about $20.2 million. Another $175 million tranche is available, and management says it expects to draw it "unless we are able to meet our financing requirements through more favorable funding sources."
• A stockholders' deficit of $173.5 million (liabilities exceed assets on the books), narrowed from $659.6 million at year-end thanks to the offering.

Runway math. The new guidance of $860–890 million includes $130–140 million of stock-based compensation, which implies roughly $720–760 million of cash operating costs for 2026 before any revenue offsets it. First-half R&D plus SG&A was $402.6 million, so the guidance implies $457–487 million in the second half, or about $230–245 million a quarter versus $202.2 million in Q2. Even at that higher pace and with modest sales, $1.70 billion covers roughly two years of spending. The 10-Q itself commits only to "at least the next 12 months," which is the standard minimum disclosure. The share sale removed the near-term funding question. The open question is now whether sales grow fast enough to stop the cash decline before the 2027–2031 debt comes due.

Takeaway: U.S. MYQORZO sales grew almost 5x in one quarter, and the May raise means Cytokinetics doesn't have to sell stock or borrow at a bad moment. But the company is deliberately spending more, not less. Guidance implies quarterly operating costs rising toward ~$240 million as it prepares a second launch in non-obstructive HCM. Breakeven depends on MYQORZO sales growing several-fold from a $100 million annual run-rate, not on cost control.

What to watch next

• November 14, 2026 FDA decision date (PDUFA) on adding MAPLE-HCM results to the U.S. label. In that trial, aficamten alone beat metoprolol, a standard first-line heart drug. Approval would support using MYQORZO earlier in treatment.
• Non-obstructive HCM filing in Q4 2026. ACACIA-HCM met both of its main goals (symptom scores and exercise capacity) and was published in The New England Journal of Medicine in August. Management says it is the first positive Phase 3 trial in this form of the disease, which is roughly half of all HCM patients. Ejection fraction is the share of blood the heart pumps out with each beat. Readings below 50% occurred in 10% of aficamten patients vs 1% on placebo, so expect the label and monitoring requirements to be part of the review.
• Europe and Japan. Management expects launches in more than five additional European markets by the first half of 2027. The UK approval came in July, with launch expected later in 2026. Bayer's Japan trial (CAMELLIA-HCM) is expected to finish in Q3 2026. Up to €70 million of further Bayer milestones are tied to first sales in Japan and in U.S. nHCM.
• Pipeline: COMET-HF (omecamtiv mecarbil in severe heart failure) keeps enrolling through 2026. AMBER-HFpEF (ulacamten) cohort 1 enrollment is expected to finish in the second half of 2026. The FDA lifted a partial clinical hold on CK-089 in Q2.

Our read: Q3 is the first quarter where U.S. demand can be judged without launch-month noise, and German stocking won't repeat. The figure to watch is U.S. net product revenue growth quarter over quarter, set against the roughly $25–40 million of extra quarterly operating cost the guidance implies for the second half.